Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: limitsubjectof normalivtherapy
  Phrases that lowered it: impairmentthe pharmacokineticspharmacokineticand safetyopen label
• Drug's FAERS reports with a death: 38.9% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 126 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 12.5% (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 95.8% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 632 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment NCT01140607 · started 2010 · scored riskier than 24% of active trials completed
• A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer NCT00925743 · started 2009 · scored riskier than 15% of active trials completed
• Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors NCT01751308 · started 2013 · scored riskier than 67% of active trials completed
• Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment NCT02204332 · started 2013 · scored riskier than 55% of active trials terminated
• Cabazitaxel in Relapsed and Metastatic NSCLC NCT01852578 · started 2012 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.